Syndax Pharmaceuticals Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $172.4 | $23.7 | $0.0 | $0.0 | $139.7 |
| Operating income | -$273.1 | -$339.7 | -$230.0 | -$151.8 | $26.2 |
| Net income | -$285.4 | -$318.8 | -$209.4 | -$149.3 | $24.9 |
| Balance Sheet | |||||
| Total debt | — | — | — | — | $20.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$323.2 | -$274.9 | -$160.6 | -$133.7 | $29.0 |
Shares outstanding 89.3M · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of September 28, 2026.